Nyxoah Announces Preliminary Results for the Second Quarter of 2026
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported preliminary, unaudited Q2 2026 results: global net revenue expected at ~€7.7m (+21% sequential) and U.S. net revenue ~€5.2m (+22%). U.S. metrics included 55 surgeons trained and 89 new accounts activated. CMS proposed 12% hospital and 15% ASC reimbursement increases for Genio. Cash/assets expected ~€97.8m; €36m–€40m full-year guidance.
How this was made
The 30-second read
Why it matters
The key trading inputs are (1) preliminary Q2 revenue estimates with sequential growth, (2) U.S. commercial traction metrics, (3) CMS-proposed reimbursement increases for the Genio procedure and ASC setting, and (4) $110M financing secured plus expected cash level at June 30, 2026.
Market read
Investors get a near-term update on NYXH’s U.S. commercial momentum and a potential reimbursement tailwind, alongside liquidity/financing details, ahead of the next reporting and investor event.
What to watch
The article doesn’t quantify margins, cash burn trajectory, or whether the financing terms materially reduce future dilution/overhang beyond stating $110M secured in Q2.
Background
Nyxoah is a medical technology company commercializing the Genio hypoglossal neurostimulation system for obstructive sleep apnea (OSA).
Ticker impact
Nyxoah (NYXH) reports preliminary Q2’26 net revenue of ~€7.7M (+21% sequential) and U.S. net revenue of ~€5.2M (+22%).
Likely positive near-term bias if investors view the sequential growth and reimbursement proposal as de-risking the path to profitability; magnitude depends on how the market compares these estimates to expectations.
The article provides concrete preliminary financial estimates, U.S. operating KPIs (active accounts, surgeon training, prior-auth submissions), and specific CMS-proposed reimbursement increases for the Genio procedure and ASC setting.
Market effects
Reimbursement optimism for neuromodulation/OSA device procedures could improve sentiment toward other medtech players tied to similar reimbursement pathways.
Primarily U.S.-focused read-through given the CMS proposal and U.S. commercial KPIs.
Limited global spillover beyond OSA neuromodulation medtech, since the disclosed catalysts are U.S.-reimbursement and NYXH-specific commercial metrics.
Counterpoint
Preliminary, unaudited estimates may not hold in final reported results; reimbursement increases are only proposed and could change during the rulemaking process.
Key entities
- companyNyxoah SA
Medical technology company developing and commercializing the Genio neuromodulation therapy for OSA; subject of the preliminary Q2’26 results and U.S. reimbursement commentary.
- regulatorCMS (Centers for Medicare & Medicaid Services)
Proposes hospital outpatient and ASC reimbursement increases for the Genio procedure (C8011) and ASC payment.
- medical_procedureGenio procedure (C8011)
The reimbursed procedure for which CMS proposes an increase from $31,526 to $35,414.
